Nika Pharmaceuticals, Inc (NIKA) Cash & Equivalents (2021 - 2023)

Nika Pharmaceuticals (NIKA) has 3 years of Cash & Equivalents data on file, last reported at $864.0 in Q4 2023.

• Quarterly Cash & Equivalents changed 0.0% year-over-year to $864.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $864.0 (changed 0.0% YoY) and the FY2023 annual result came in at $864.0, changed 0.0% from the prior year.
• Cash & Equivalents declined to $864.0 in Q4 2023, from $10910.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $11053.0 in Q2 2023 to a low of $83.0 in Q1 2022.
• A 3-year average of $3560.2 and a median of $1528.0 in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 93.88% — and 2023, when it surged 5272.29%.
• Tracing NIKA's Cash & Equivalents over 3 years: stood at $399.0 in 2021, then surged by 116.54% to $864.0 in 2022, then changed by 0.0% to $864.0 in 2023.
• The last three Cash & Equivalents figures came in at $864.0 (Q4 2023), $10910.0 (Q3 2023), and $11053.0 (Q2 2023), per Business Quant data.